General information
ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Bavaria
Germany
Contact person: Steffen Schuster, Chief Executive Officer
Company main phone: +49 (89) 32989866000
Company main fax: +49 (89) 32989866061
Website: itm-radiopharma.com
Year founded: | 2004
|
Source of foundation: | Independent foundation |
Corporate description / mission:
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector: |
- Pharma (fully integrated)
|
Subsector: |
- Antibodies
- Peptides
- Other
|
Primary therapeutic areas: |
- Neoplasms / cancer / oncology
|
Business model: |
- Manufacturer
- R&D
- Supplier / Distributor
|
Customer segments: |
- Large biotech & big pharma
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 4 | |
Phase I: | 1 | |
Phase III: | 3 | |
On the market: | 1 | |
Description of products:
ITM-41
ITM-52
ITM-55D
ITM-22
etc.
Collaborations & Clients
Partnering strategy / collaborations:
The company is always seeking innovative drug discovery partnerships, ideally fusing their target know-how with their leading radioisotope platform technologies to develop next generation diagnostic and therapeutic agents that will help fight serious and difficult to treat cancer diseases.